Shares of Lupin Ltd., Shilpa Medicare Ltd., and Natco Pharma Ltd. are in focus after recent inspections by the US Food and Drug Administration (USFDA) resulted in observations. Alkem Laboratories Ltd. reported no critical findings from its inspection. Investors are closely watching how these companies address the regulatory feedback.